• Oseltamivir acid Research Workflow Guide

  2026-09-22

  Build more reliable influenza neuraminidase assays with Oseltamivir acid, from fresh-solution handling to resistance-aware viral readouts. The workflow also shows how human-relevant exposure studies and carefully controlled breast-cancer models can extend interpretation beyond a single antiviral endpoint.

• Etomoxir as a Translational Tool for Immunometabolism

  2026-09-22

  Etomoxir is more than a fatty acid oxidation inhibitor: it is a strategic perturbation tool for connecting mitochondrial substrate use with immune-cell function. This thought-leadership article explains how to use Etomoxir and R-(+)-Etomoxir in standardized whole-blood assays, interpret concentration-dependent pharmacology, compare experimental platforms, and build a translational path toward metabolic disorder research and neuroinflammation research.

• O-GlcNAc, HUWE1, and Ferroptosis in Preeclampsia

  2026-09-21

  The reference study identifies an O-GlcNAc–HUWE1–TfR1 pathway that links placental protein modification to iron handling, ferroptosis, and trophoblast syncytialization in preeclampsia. Its combination of modification proteomics, mechanistic validation, and mouse studies provides a framework for testing how OGT-dependent signaling influences placental stress.

• FXR Phase Separation Clusters Coronavirus Organelles

  2026-09-21

  Li et al. show that fragile X–related proteins organize β-coronavirus double-membrane vesicles through liquid–liquid phase separation, linking replication-organelle architecture to local translation and SARS-CoV-2 replication. The study combines cellular perturbation, membrane reconstitution, condensate assays, and infection experiments to define FXR proteins as host factors that spatially concentrate viral replication machinery.

• Lisinopril dihydrate: ACE Inhibition Workflows

  2026-09-20

  Lisinopril dihydrate provides a practical, water-compatible probe for connecting ACE target engagement with hypertension, cardiac injury, and renal disease phenotypes. This guide emphasizes concentration-range design, peptidase selectivity controls, solution handling, and troubleshooting for more reproducible translational experiments.

• Measuring Cancer Drug Response Beyond Viability

  2026-09-19

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell killing are related but non-equivalent dimensions of anticancer drug response. This framework helps researchers design in vitro studies that separate proliferative arrest from cytotoxicity and interpret response timing more rigorously.

• Pravastatin Sodium: From Mechanism to Translation

  2026-09-18

  Pravastatin sodium is more than a familiar lipid-lowering tool. Its selective HMG-CoA reductase inhibition, macrophage activity, and transporter-dependent hepatocyte handling create a practical framework for translational studies spanning cholesterol biology, metabolic disease, and carefully bounded exploratory oncology research.

• FDA-Approved Drug Screen Finds MERS-CoV Inhibitors

  2026-09-18

  de Wilde and colleagues screened 348 FDA-approved compounds in cell culture and identified four molecules, including Lopinavir, that inhibited MERS-CoV replication at low-micromolar concentrations. The study provides a practical repurposing framework for emerging coronavirus research while showing why cell-based antiviral activity must be separated from claims about mechanism, clinical efficacy, or coronavirus-specific drug development.

• (S,S)-Nanaomycin A: DNMT3B Research

  2026-09-17

  Explore how (S,S)-Nanaomycin A can be used to interrogate DNMT3B-driven lineage plasticity in neuroendocrine prostate cancer. This guide translates recent mechanistic findings into practical assay design, controls, and interpretation strategies.

• Lysosomal Exocytosis in MPS IVA Cartilage

  2026-09-17

  This study identifies enhanced lysosomal exocytosis and disease-specific growth factor disruption as contributors to cartilage pathology in a zebrafish model of mucopolysaccharidosis type IVA. Its comparative analysis shows that increased exocytosis does not uniformly raise extracellular protease activity, highlighting the importance of lysosomal cargo, glycosaminoglycan balance, and tissue context.

• Sulfo-Cy5 Carboxylic Acid for Assay Design

  2026-09-16

  Sulfo-Cy5 carboxylic acid combines aqueous compatibility with bright far-red fluorescence for life-science assays. This article explains how its chemistry can support protein labeling, nanoparticle tracking, and fluorescence imaging while avoiding common interpretation errors.

• From ZNF263–STAT3 to CD4-Aware Translation

  2026-09-16

  A translational framework linking the ZNF263–STAT3 axis and chemoradiotherapy resistance in colorectal cancer with disciplined, CD4-aware immune assay design using Recombinant Mouse CD4, Tag Free.

• EZ Cap™ Reagent GG and p21 mRNA Delivery

  2026-09-15

  EZ Cap™ Reagent GG is an mRNA capping reagent identified as SKU B8177, but the supplied MSDS does not establish its cap structure or IVT performance. A 2026 FASEB Journal study supports intravesical p21 mRNA–LNP delivery as a localized bladder-cancer research strategy, while product-specific validation remains necessary.

• Selonsertib (GS-4997): Mapping Stress–Autophagy Causality

  2026-09-15

  Selonsertib (GS-4997) enables a causal assay strategy for separating ASK1 stress signaling from Galectin-1–FIP200 autophagy failure in hepatic steatosis research. This article translates the latest mechanistic findings into practical workflows for inflammation, fibrosis, and metabolic disease studies.

• Trelagliptin, RUNX2, and Osteoblastic Differentiation

  2026-09-14

  The reference study identifies a potential bone-forming action of the DPP-4 inhibitor trelagliptin in MC3T3-E1 cells, connecting enhanced mineralization with RUNX2 induction and AMPK signaling. Its findings support further osteoporosis research but remain an in vitro mechanistic observation requiring validation in primary cells, animal models, and clinical settings.

8012 records 1/535 page Next 12345 下5页 Last page